NICE publish final draft guidelines for GSK’s gene therapy, Strimvelis
NICE have now published final draft guidance approving GlaxoSmithKline’s gene therapy Strimvelis for an ultra-rare immune deficiency condition commonly referred to as bubble baby syndrome. Severe combined immunodeficiency due to adenosine deaminase deficiency, (ADA-SCID) is an inherited genetic condition affecting the body’s white blood cells, that renders the body’s immune system unable to function properly,